StockNews.com Downgrades Repligen (NASDAQ:RGEN) to Sell

StockNews.com lowered shares of Repligen (NASDAQ:RGEN - Free Report) from a hold rating to a sell rating in a report published on Friday morning.

A number of other research analysts have also recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Friday. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They set a "peer perform" rating for the company. Canaccord Genuity Group lifted their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research report on Friday. Royal Bank of Canada increased their price target on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday. Finally, TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and an average price target of $181.00.

Remove Ads

Repligen Price Performance

Shares of NASDAQ RGEN traded down $3.27 during midday trading on Friday, hitting $161.47. The company had a trading volume of 801,294 shares, compared to its average volume of 624,058. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a 50-day simple moving average of $155.30 and a two-hundred day simple moving average of $148.57. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The firm has a market capitalization of $9.05 billion, a price-to-earnings ratio of -316.61, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Equities research analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Signaturefd LLC boosted its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new position in shares of Repligen during the 4th quarter worth about $29,000. Raiffeisen Bank International AG acquired a new stake in shares of Repligen in the fourth quarter worth approximately $29,000. Blue Trust Inc. grew its holdings in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 127 shares during the period. Finally, Resources Management Corp CT ADV acquired a new position in Repligen during the third quarter worth approximately $37,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.